Clinical Trials

List clinical trials by disease

The results of your search are listed below. To view the details of a trial or study, click on the "see details >>" link. Or start a new search.

Searched for: Brain Cancer. 9 results shown below.

Bendamustine Hydrochloride in Treating Patients With Recurrent or Progressive Anaplastic Glioma

[Complete title: A Phase II Study of Bendamustine in the Treatment of Recurrent High-Grade Gliomas (Anaplastic Gliomas and Glioblastoma)]
Principal Investigator: Marc Chamberlain, MD
Study Number: 6803
Phase: II

Bevacizumab Versus Bevacizumab Plus Vorinostat in Adults With Recurrent Glioblastoma

[Complete title: Phase I/II Adaptive Randomized Trial of Bevacizumab versus Bevacizumab plus Vorinostat in Adults with Recurrent Glioblastoma]
Principal Investigator: Marc Chamberlain, MD
Study Number: 7994
Phase: I/II

RTOG 1205: Randomized Phase II Trial of Concurrent Bevacizumab and Re-Irradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma
Principal Investigator: George Laramore, MD, PhD
Study Number: 8024
Phase: II

Efficacy of Carboplatin Administered Concomitantly with Radiation and Isoretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients
Principal Investigator: James Olson, MD, PhD
Study Number: ACNS0332
Phase: III

A Study Evaluating Limited Target Volume Boost Irradiation and Reduced Dose Craniospinal Radiotherapy 18.00 Gy and Chemotherapy In Children with Newly Diagnosed Standard Risk Medulloblastoma: A Phase III Double Randomized Trial
Principal Investigator: J. Russell Geyer, MD
Study Number: ACNS0331
Phase: III

A Phase I Study of Temozolomide, oral Irinotecan and Vincristine for Children with Refractory Solid Tumors
Principal Investigator: Julie Park, MD
Study Number: COG ADVL0414
Phase: I

Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM)

[Complete title: A Prospective, Multi-center Trial of NovoTTF-100A Together With Temozolomide Compared to Temozolomide Alone in Patients with Newly Diagnosed GBM]
Principal Investigator: Maciej Mrugala, MD, PhD
Study Number: 20090487
Phase: III

Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma (ACT IV)

[Complete title: An International, Randomized, Double-Blind, Controlled Study of Rindopepimut/GM-CSF with Adjuvant Temozolomide in Patients with Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma]
Principal Investigator: Maciej Mrugala, MD, PhD
Study Number: 20111531
Phase: III

A Phase 1b/2 Study of PLX3397 + Radiation Therapy + Temozolomide in Patients With Newly Diagnosed Glioblastoma

[Complete title: An Open Label Phase 1b/2 Study of Orally Administered PLX3397 in Combination with Radiation Therapy and Temozolomide in Patients with Newly Diagnosed Glioblastoma]
Principal Investigator: Marc Chamberlain, MD
Study Number: 20131088
Phase: I/II

Search Options

Select a disease from the list below:
Limit results to studies enrolling:

OR

Search by Keyword, Investigator Name or Study ID#:
Limit results to studies enrolling:

OR

View all studies
Limit results to studies enrolling:

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials

Fred Hutchinson Cancer Research Center is a world leader in research to prevent, detect and treat cancer and other life-threatening diseases.